Health & bio
Eli Lilly's Orforglipron (Foundayo) Gains FDA Approval
72-week average weight loss: 12% vs. 0.9% placebo. First GLP-1 tablet without meal restrictions.
Primary sources · 1
72-week average weight loss: 12% vs. 0.9% placebo. First GLP-1 tablet without meal restrictions.
7 must-reads · 17 fields · tracked storylines delivered to your inbox daily. Pick only the fields you want; unsubscribe anytime.